Kathleen Large
Chief Tech/Sci/R&D Officer bei TRILLIUM THERAPEUTICS
Profil
Kathleen Large is a professional with experience in the pharmaceutical industry.
She is currently the Senior Vice President-Clinical Operations at Trillium Therapeutics ULC since 2019.
Previously, she worked as Vice President-Clinical Development at Histogenics Corp.
and as Vice President-Development Operations at Aileron Therapeutics, Inc. from 2018 to 2019.
Ms. Large completed her undergraduate degree at Boston College and her graduate degree at The University of California, San Francisco.
Aktive Positionen von Kathleen Large
| Unternehmen | Position | Beginn |
|---|---|---|
| TRILLIUM THERAPEUTICS | Chief Tech/Sci/R&D Officer | 01.01.2019 |
Ehemalige bekannte Positionen von Kathleen Large
| Unternehmen | Position | Ende |
|---|---|---|
| AILERON THERAPEUTICS, INC. | Corporate Officer/Principal | 01.01.2019 |
| OCUGEN, INC. | Corporate Officer/Principal | - |
Ausbildung von Kathleen Large
| Boston College | Undergraduate Degree |
| The University of California, San Francisco | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AILERON THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Trillium Therapeutics ULC
 Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
Histogenics Corp.
 Histogenics Corp. BiotechnologyHealth Technology Histogenics Corp. engages in the development, marketing, and commercialization of restorative cell therapies. Its regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives, and growth factors to provide solutions that can be utilized individually and in concert to treat musculoskeletal-related conditions. The company was founded on June 28, 2000 and is headquartered in Waltham, MA. | Health Technology |
